Privately held Iambic said on Monday it has entered a multi-year partnership worth more than $1.7 billion with Japan's Takeda Pharmaceutical to use artificial intelligence to help design ...

Iambic, a clinical-stage life science and technology company that uses artificial intelligence to develop medicines has raised more than $100 million in an oversubscribed financing round. The Nov. 10 ...

There’s a post-”Gladiator,” (and also post-“Lord of the Rings”) soundscape that we kind of expect from period pieces — a certain amount of wagons rolling and armor clanging and chickens chirping and ...

Iambic has encouraging early clinical data for its lead program, a breast cancer drug that could offer advantages over other therapies in its class. Now the biotech has $100 million to support further ...

Iambic integrates physics principles into its AI architectures, creating models aimed at going deeper into the chemical space. Iambic's platforms include Enchant, NeuralPLexar and OrbNet. Enchant is a ...

SAN DIEGO, October 21, 2025--(BUSINESS WIRE)--Iambic Therapeutics, a clinical-stage life science and technology company developing novel medicines using its AI-driven discovery and development ...

(Reuters) -Iambic Therapeutics said on Monday early-stage data of its experimental drug showed anti-tumor activity in heavily pretreated cancer patients with mutations in the HER2 gene. The drug ...

Right before the second phase of Honkai Star Rail 3.6, Pure Fiction, one of the title’s endgame activities was refreshed. Players can now challenge it again to obtain a decent amount of Stellar Jade.

Michael Oren, the American-born historian, writer, and former Israeli diplomat, writes a Substack called Clarity, one of the few blogs I read not just for its insights but for the fluency with which ...

OpenAI on Thursday unveiled its new version of ChatGPT, GPT-5, with the company’s CEO Sam Altman calling it “a major upgrade” from the previous version. “Thirty-two months ago, we launched ChatGPT.

REDWOOD CITY, Calif. and SAN DIEGO, July 09, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with ...